Humira’s PMS ends on August, triggering biosimilar development competition

The domestic PMS(post marketing surveillance) of Humira(adalimumab, Abbvie), a rheumatoid arthritis treatment having the globally KRW 16 trillion sales market, will end this August.

Since the development of Humira biosimilars is so active, the competition for the exclusive sales rights under the Patent-Linkage System is expected to be accelerated.

According to the confirmed result of the Mi...